1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => FreeToRead
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


  
    























































































































    Do All Patients with Multiple Sclerosis Benefit from the Use of Contrast on Serial Follow-Up MR Imaging? A Retrospective Analysis | American Journal of Neuroradiology  
    

















    





























    
  
  




    
    

  

      


    

      

  
  
  

    

  

    

  

                
    

      

  

    

  
      
  
  

    


Advertisement



  



  


  
  



  



    

  


  


  


  
  
  
  
  
  

  	      



          


    
      

    
  
    
        
    

  

    
                        

  

                
    

      

	  

		
		

			

			  

  
      
  
  

    

  
  
      
Research ArticleAdult Brain

  
      

  
      
Do All Patients with Multiple Sclerosis Benefit from the Use of Contrast on Serial Follow-Up MR Imaging? A Retrospective Analysis
  
    	
R.R. Mattay, K. Davtyan, M. Bilello and A.C. Mamourian

  
    	
American Journal of Neuroradiology November 2018,  39 (11) 2001-2006; DOI: https://doi.org/10.3174/ajnr.A5828 

  
  
  



  


  
  



			

		

	
	
 	
	  
  

		
		

			

			  

  
      
  
  

    
  


  
  



  
      
  
  

    

  

    

  
      
  
  

    
References
  1. 1.↵
    1. 

    2. Rovira  À, 
    3. Wattjes  MP, 
    4. Tintoré  M, et al
    ; MAGNIMS study group. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. Nat Rev Neurol 2015;11:471–82 doi:10.1038/nrneurol.2015.106 pmid:26149978
    CrossRefPubMed
  2. 2.↵
    1. 

    2. Traboulsee  A, 
    3. Simon  JH, 
    4. Stone  L, et al
    . Revised recommendations of the Consortium of MS Centers Task Force for a standardized MRI protocol and clinical guidelines for the diagnosis and follow-up of multiple sclerosis. AJNR Am J Neuroradiol 2016;37:394–401 doi:10.3174/ajnr.A4539 pmid:26564433
    Abstract/FREE Full Text
  3. 3.↵
    1. 

    2. Simon  JH, 
    3. Li  D, 
    4. Traboulsee  A, et al
    . Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. AJNR Am J Neuroradiol 2006;27:455–61 pmid:16484429
    FREE Full Text
  4. 4.↵
    1. 

    2. Rovira  A, 
    3. Auger  C, 
    4. Alonso  J
    . Magnetic resonance monitoring of lesion evolution in multiple sclerosis. Ther Adv Neurol Disord 2013;6:298–310 doi:10.1177/1756285613484079 pmid:23997815
    CrossRefPubMed
  5. 5.↵
    1. 

    2. Cotton  F, 
    3. Weiner  HL, 
    4. Jolesz  FA, et al
    . MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology 2003;60:640–46 doi:10.1212/01.WNL.0000046587.83503.1E pmid:12601106
    Abstract/FREE Full Text
  6. 6.↵
    1. 

    2. Absinta  M, 
    3. Sati  P, 
    4. Reich  DS
    . Advanced MRI and staging of multiple sclerosis lesions. Nat Rev Neurol 2016;12:358–68 doi:10.1038/nrneurol.2016.59 pmid:27125632
    CrossRefPubMed
  7. 7.↵
    1. 

    2. Frischer  JM, 
    3. Bramow  S, 
    4. Dal-Bianco  A, et al
    . The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009;132(Pt 5):1175–89 doi:10.1093/brain/awp070 pmid:19339255
    CrossRefPubMedWeb of Science
  8. 8.↵
    1. 

    2. Hammond  KE, 
    3. Metcalf  M, 
    4. Carvajal  L, et al
    . Quantitative in vivo magnetic resonance imaging of multiple sclerosis at 7 Tesla with sensitivity to iron. Ann Neurol 2008;64:707–13 doi:10.1002/ana.21582 pmid:19107998
    CrossRefPubMedWeb of Science
  9. 9.↵
    1. 

    2. Absinta  M, 
    3. Sati  P, 
    4. Gaitan  MI, et al
    . Seven-Tesla phase imaging of acute multiple sclerosis lesions: a new window into the inflammatory process. Ann Neurol 2013;74:669–78 doi:10.1002/ana.23959 pmid:23813441
    CrossRefPubMed
  10. 10.↵
    1. 

    2. Mehta  V, 
    3. Pei  W, 
    4. Yang  G, et al
    . Iron is a sensitive biomarker for inflammation in multiple sclerosis lesions. PLoS One 2013;8:e57573 doi:10.1371/journal.pone.0057573 pmid:23516409
    CrossRefPubMed
  11. 11.↵
    1. 

    2. Pitt  D, 
    3. Boster  A, 
    4. Pei  W, et al
    . Imaging cortical lesions in multiple sclerosis with ultra-high-field magnetic resonance imaging. Arch Neurol 2010;67:812–18 doi:10.1001/archneurol.2010.148 pmid:20625086
    CrossRefPubMedWeb of Science
  12. 12.↵
    1. 

    2. Bagnato  F, 
    3. Hametner  S, 
    4. Yao  B, et al
    . Tracking iron in multiple sclerosis: a combined imaging and histopathological study at 7 Tesla. Brain 2011;134:3602–15 doi:10.1093/brain/awr278 pmid:22171355
    CrossRefPubMed
  13. 13.↵
    1. 

    2. Bian  W, 
    3. Harter  K, 
    4. Hammond-Rosenbluth  KE, et al
    . A serial in vivo 7T magnetic resonance phase imaging study of white matter lesions in multiple sclerosis. Mult Scler 2013;19:69–75 doi:10.1177/1352458512447870 pmid:22641301
    CrossRefPubMed
  14. 14.↵
    1. 

    2. Yao  B, 
    3. Bagnato  F, 
    4. Matsuura  E, et al
    . Chronic multiple sclerosis lesions: characterization with high-field-strength MR imaging. Radiology 2012;262:206–15 doi:10.1148/radiol.11110601 pmid:22084205
    CrossRefPubMedWeb of Science
  15. 15.↵
    1. 

    2. Hagemeier  J, 
    3. Heininen-Brown  M, 
    4. Poloni  GU, et al
    . Iron deposition in multiple sclerosis lesions measured by susceptibility-weighted imaging filtered phase: a case control study. J Magn Reson Imaging 2012;36:73–83 doi:10.1002/jmri.23603 pmid:22407571
    CrossRefPubMed
  16. 16.↵
    1. 

    2. Choi  SR, 
    3. Howell  OW, 
    4. Carassiti  D, et al
    . Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. Brain 2012;135(Pt 10):2925–37 doi:10.1093/brain/aws189 pmid:22907116
    CrossRefPubMedWeb of Science
  17. 17.↵
    1. 

    2. Lucchinetti  CF, 
    3. Popescu  BF, 
    4. Bunyan  RF, et al
    . Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 2011;365:2188–97 doi:10.1056/NEJMoa1100648 pmid:22150037
    CrossRefPubMedWeb of Science
  18. 18.↵
    1. 

    2. Popescu  BF, 
    3. Lucchinetti  CF
    . Meningeal and cortical grey matter pathology in multiple sclerosis. BMC Neurol 2012;12:11 doi:10.1186/1471-2377-12-11 pmid:22397318
    CrossRefPubMed
  19. 19.↵
    1. 

    2. Magliozzi  R, 
    3. Howell  OW, 
    4. Reeves  C, et al
    . A gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol 2010;68:477–93 doi:10.1002/ana.22230 pmid:20976767
    CrossRefPubMedWeb of Science
  20. 20.↵
    1. 

    2. Magliozzi  R, 
    3. Howell  O, 
    4. Vora  A, et al
    . Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007;130(Pt 4):1089–104 pmid:17438020
    CrossRefPubMedWeb of Science
  21. 21.↵
    1. 

    2. Howell  OW, 
    3. Reeves  CA, 
    4. Nicholas  R, et al
    . Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 2011;134(Pt 9):2755–71 doi:10.1093/brain/awr182 pmid:21840891
    CrossRefPubMedWeb of Science
  22. 22.↵
    1. 

    2. Daams  M, 
    3. Geurts  JJ, 
    4. Barkhof  F
    . Cortical imaging in multiple sclerosis: recent findings and ‘grand challenges.’ Curr Opin Neurol 2013;26:345–52 doi:10.1097/WCO.0b013e328362a864 pmid:23812306
    CrossRefPubMed
  23. 23.↵
    1. 

    2. Eisele  P, 
    3. Griebe  M, 
    4. Szabo  K, et al
    . Investigation of leptomeningeal enhancement in MS: a postcontrast FLAIR MRI study. Neurology 2015;84:770–75 doi:10.1212/WNL.0000000000001286 pmid:25616480
    CrossRefPubMed
  24. 24.↵
    1. 

    2. Absinta  M, 
    3. Vuolo  L, 
    4. Rao  A, et al
    . Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis. Neurology 2015;85:18–28 doi:10.1212/WNL.0000000000001587 pmid:25888557
    Abstract/FREE Full Text
  25. 25.↵
    1. 

    2. Zivadinov  R, 
    3. Ramasamy  DP, 
    4. Vaneckova  M, et al
    . Leptomeningeal contrast enhancement is associated with progression of cortical atrophy in MS: a retrospective, pilot, observational longitudinal study. Mult Scler 2017;23:1336–45 doi:10.1177/1352458516678083 pmid:27811339
    CrossRefPubMed
  26. 26.↵
    1. 

    2. Miller  DH, 
    3. Barkhof  F, 
    4. Nauta  JJ
    . Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain 1993;116:1077–94 doi:10.1093/brain/116.5.1077 pmid:8221048
    CrossRefPubMedWeb of Science
  27. 27.↵
    1. 

    2. Milo  R, 
    3. Kahana  E
    . Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev 2010;9:A387–94 doi:10.1016/j.autrev.2009.11.010 pmid:19932200
    CrossRefPubMedWeb of Science
  28. 28.↵
    1. 

    2. Brønnum-Hansen  H, 
    3. Koch-Henriksen  N, 
    4. Stenager  E
    . Trends in survival and cause of death in Danish patients with multiple sclerosis. Brain 2004;127(Pt 4):844–50 doi:10.1093/brain/awh104 pmid:14960501
    CrossRefPubMedWeb of Science
  29. 29.↵
    1. 

    2. Kanda  T, 
    3. Ishii  K, 
    4. Kawaguchi  H, et al
    . High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 2014;270:834–41 doi:10.1148/radiol.13131669 pmid:24475844
    CrossRefPubMed
  30. 30.↵
    1. 

    2. Kanda  T, 
    3. Fukusato  T, 
    4. Matsuda  M, et al
    . Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology 2015;276:228–32 doi:10.1148/radiol.2015142690 pmid:25942417
    CrossRefPubMed
  31. 31.↵
    1. 

    2. McDonald  RJ, 
    3. McDonald  JS, 
    4. Kallmes  DF, et al
    . Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology 2015;275:772–82 doi:10.1148/radiol.15150025 pmid:25742194
    CrossRefPubMed
  32. 32.↵
    1. 

    2. Murata  N, 
    3. Gonzalez-Cuyar  LF, 
    4. Murata  K, et al
    . Macrocyclic and other non-group 1 gadolinium contrast agents deposit low levels of gadolinium in brain and bone tissue: preliminary results from 9 patients with normal renal function. Invest Radiol 2016;51:447–53 doi:10.1097/RLI.0000000000000252 pmid:26863577
    CrossRefPubMed
  33. 33.↵
    1. 

    2. McDonald  RJ, 
    3. McDonald  JS, 
    4. Kallmes  DF, et al
    . Gadolinium deposition in human brain tissues after contrast-enhanced MR imaging in adult patients without intracranial abnormalities. Radiology 2017;285:546–54 doi:10.1148/radiol.2017161595 pmid:28653860
    CrossRefPubMed
  34. 34.↵
    FDA Drug Safety Communication: FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings. https://www.fda.gov/Drugs/DrugSafety/ucm589213.htm. Accessed March 5, 2018. 
  35. 35.↵
    1. 

    2. Gupta  A, 
    3. Al-Dasuqi  K, 
    4. Xia  F, et al
    . The use of noncontrast quantitative MRI to detect gadolinium-enhancing multiple sclerosis brain lesions: a systematic review and meta-analysis. AJNR Am J Neuroradiol 2017;38:1317–22 doi:10.3174/ajnr.A5209 pmid:28522663
    Abstract/FREE Full Text
  36. 36.↵
    1. 

    2. Wattjes  MP, 
    3. Rovira  À, 
    4. Miller  D, et al
    ; MAGNIMS study group. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients. Nat Rev Neurol 2015;11:597–606 doi:10.1038/nrneurol.2015.157 pmid:26369511
    CrossRefPubMed
  37. 37.↵
    1. 

    2. Bilello  M, 
    3. Arkuszewski  M, 
    4. Nucifora  P, et al
    . Multiple sclerosis: identification of temporal changes in brain lesions with computer-assisted detection software. Neuroradiol J 2013;26:143–50 doi:10.1177/197140091302600202 pmid:23859235
    CrossRefPubMed
  38. 38.↵
    1. 

    2. Dutta  R, 
    3. Trapp  BD
    . Relapsing and progressive forms of multiple sclerosis: insights from pathology. Curr Opin Neurol 2014;27:271–78 doi:10.1097/WCO.0000000000000094 pmid:24722325
    CrossRefPubMed
  39. 39.↵
    1. 

    2. Treabă  CA, 
    3. Bălaşa  R, 
    4. Podeanu  DM, et al
    . Cerebral lesions of multiple sclerosis: is gadolinium always irreplaceable in assessing lesion activity? Diagn Interv Radiol 2014;20:178–84 doi:10.5152/dir.2013.13313 pmid:24378990
    CrossRefPubMed
  40. 40.↵
    1. 

    2. Guranda  M, 
    3. Essig  M, 
    4. Poulin  A, et al
    . Fluid-attenuated inversion recovery signal intensity as a predictor of gadolinium enhancement in relapsing-remitting multiple sclerosis. Int J MS Care 2018;20:62–66 doi:10.7224/1537-2073.2016-053 pmid:29670492
    CrossRefPubMed
  41. 41.↵
    1. 

    2. Elster  AD, 
    3. Mirza  W
    . MR imaging in chronic partial epilepsy: role of contrast enhancement. AJNR Am J Neuroradiol 1991;12:165–70 pmid:1903576
    Abstract/FREE Full Text
  42. 42.↵
    1. 

    2. Dworkin  JD, 
    3. Linn  KA, 
    4. Oguz  I, et al
    ; North American Imaging in Multiple Sclerosis Cooperative. An automated statistical technique for counting distinct multiple sclerosis lesions. AJNR Am J Neuroradiol 2018;39:626–33 doi:10.3174/ajnr.A5556 pmid:29472300
    Abstract/FREE Full Text
  


  
  



  




  


  
  



  
      
  
  

    
  


  
  



  
      
  
  

     Back to top  


  
  



			

		

		
		

			

			  

  
        
In this issue

    
  
  

    
  


  
  



  
      
  
  

    

  

    

  
      
  
  

    


Advertisement



  



  


  
  



  



  


  
  



  
      
  
  

    

	  
  

		

          

            

  
      
  
  

     Print  


  
  



  
      
  
  

     Download PDF  


  
  



  
      
  
  

    
 Email Article
  


  
  



  
      
  
  

    
 Citation Tools
  


  
  



          

        

        
        

          

            



  
      
  
  

    

  

    

  
      
  
  

    

  
  
  
  
      
Do All Patients with Multiple Sclerosis Benefit from the Use of Contrast on Serial Follow-Up MR Imaging? A Retrospective Analysis
  
    	
R.R. Mattay, K. Davtyan, M. Bilello, A.C. Mamourian

  
    	
American Journal of Neuroradiology Nov 2018, 39 (11) 2001-2006; DOI: 10.3174/ajnr.A5828 

  
  
  



  


  
  



  
      
  
  

    

  
    
  
  
    
  
  
    
  


  


  
  



  
      
  
  

    
del.icio.us logo Twitter logo Facebook logo Mendeley logo
  


  
  



  



  


  
  



  
      
  
  

    
  


  
  



          

        

	
 	
	
	


  


  
  



  
      
  
  

    
              Purchase  


  
  



  
        
Jump to section

    
  
  

    
  


  
  



  
      
  
  

    
  


  
  



			

		

	
	
 	
	
	


    

  



  

                
    

      

  

    

  
      
  
  

    


Advertisement